Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

August 20, 2025 updated by: Incyte Corporation

A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a first-line platinum-containing chemotherapy regimen for advanced/metastatic disease.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
84

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Kurralta Park, Australia, 5037
        • Adelaide Cancer Centre
      • Macquarie Park, Australia, 2109
        • Macquarie University Hospital
    • New South Wales
      • Wollongong, New South Wales, Australia, 2500
        • Southern Medical Day Care Centre
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
        • Austin Health-Austin Hospital
  • Canada
      • Quebec, Canada, G1R 3S1
        • CHU de Quebec-Universite Laval-Hotel Dieu de Quebec
    • Ontario
      • London, Ontario, Canada, N6A 4L6
        • London Health Sciences Centre
      • Ottawa, Ontario, Canada, K1H 8L6
        • The Ottawa Hospital Cancer Centre
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Research Institute
    • Quebec
      • Montréal, Quebec, Canada, H1T 2M4
        • CIUSSS - Hopital Maisonneuve- Rosemont
      • Montréal, Quebec, Canada, H1T 2M4
        • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont
      • Québec, Quebec, Canada, G1R 3S1
        • CHU de Quebec-Universite Laval-Hotel Dieu de Quebec
  • Denmark
      • Aalborg, Denmark, 9000
        • Aalborg University Hospital
      • Copenhagen, Denmark, 2100
        • Rigshospitalet
      • Herlev, Denmark, 2730
        • Herlev Hospital
      • Næstved, Denmark, 4700
        • Sjaellands Universitetshospital Naestved
  • France
      • Angers, France, 49055
        • Institut de Cancerologie de l Ouest Site Paul Papin
      • Avignon, France, 84918
        • Clinique Sainte Catherine
      • Caen, France, 14000
        • Centre de Lutte Contre le Cancer François Baclesse
      • Le Mans, France, 72000
        • Clinique Victor Hugo
      • Lille, France, 59020
        • Centre Oscar Lambret
      • Lyon, France, 69008
        • Centre Leon Berard
      • Montpellier, France, 34298
        • Institut du Cancer de Montpellier
      • Paris, France, 75014
        • Hôpital Cochin
      • Paris, France, 75475
        • Hôpital Saint Louis
      • Reims, France, 51726
        • Institut Jean Godinot
      • Suresnes, France, 92151
        • Centre Médico-Chirurgical Foch
      • Tours, France, 37044
        • C.H.U. de Tours - Hopital Bretonneau
      • Villejuif, France, 94805
        • Institut Gustave Roussy
  • Germany
      • Duesseldorf, Germany, 40225
        • Universitaetsklinikum Duesseldorf
      • Hamburg, Germany, 20246
        • Universitätsklinikum Hamburg-Eppendorf
      • Jena, Germany, 07747
        • Universitaetsklinikum Jena
      • Magdeburg, Germany, 39120
        • Universitaetsklinikum Magdeburg A.o.R.
      • Muenchen, Germany, 81675
        • Klinikum rechts der Isar der Technischen Universitat
      • Tuebingen, Germany, 72076
        • Universitaetsklinikum Tuebingen
    • Schleswig Holstein
      • Luebeck, Schleswig Holstein, Germany, 23538
        • Universitaetsklinikum Schleswig-Holstein. Campus Luebeck
  • Hungary
      • Budapest, Hungary, 1122
        • Orszagos Onkologiai Intezet
      • Budapest, Hungary, 1145
        • Uzsoki Utcai Kórház
      • Kaposvár, Hungary, 7400
        • Somogy Megyei Kaposi Mor Oktato Korhaz
      • Miskolc, Hungary, 3526
        • Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz
      • Pécs, Hungary, 7624
        • Pecsi Tudomanyegyetem AOK
      • Szolnok, Hungary, 5004
        • Jasz - Nagykun Szolnok megyei Hetenyi Geza Korhaz - Rendelointezet
  • Ireland
      • Cork, Ireland
        • Cork University Hospital
      • Dublin, Ireland, 00024
        • Adelaide & Meath Hospital (Incl NCH)
      • Dublin, Ireland, 00009
        • Beaumont Hospital
      • Galway, Ireland, H91YR71
        • University College Hospital Galway
      • Limerick, Ireland, V94F858
        • University Hospital Limerick
      • Waterford, Ireland, X91ER8E
        • Waterford Regional Hospital
  • Israel
      • Be'er Sheva, Israel, 8410101
        • Soroka Medical Center
      • Haifa, Israel, 31096
        • Rambam Medical Center
      • Kfar Saba, Israel, 4428164
        • Meir Medical Center
      • Petach-Tikwa, Israel, 49100
        • Rabin Medical Center
      • Ramat Gan, Israel, 52621
        • Chaim Sheba Medical Center
      • Tel Aviv, Israel, 6423906
        • Sourasky Medical Center
      • Zerifin, Israel, 70300
        • Assaf Harofeh Medical Center
  • Italy
      • Arezzo, Italy, 52100
        • Medical Oncology Ospedale San Donato
      • Meldola, Italy, 47014
        • Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori
      • Milano, Italy, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Napoli, Italy, 80131
        • Istituto Nazionale Tumori Fondazione Pascale
      • Padova, Italy, 35128
        • Istituto Oncologico Veneto
  • Japan
      • Osaka, Japan, 541-8567
        • Osaka International Cancer Institute
      • Tokyo, Japan, 113-8519
        • Medical Hospital, Tokyo Medical and Dental University
      • Tokyo, Japan, 144-0042
        • Yusen Logistics Co Ltd,. Haneda Logistics Center (MSD DC)
    • Aichi
      • Nagoya, Aichi, Japan, 466-8560
        • Nagoya University Hospital
    • Chiba
      • Kashiwa, Chiba, Japan, 277-8577
        • National Cancer Center Hospital East
    • Ibaraki
      • Tsukuba, Ibaraki, Japan, 305-8576
        • University of Tsukuba Hospital
    • Nara
      • Kashihara, Nara, Japan, 634-8522
        • Nara Medical University Hospital
    • Yamaguchi
      • Ube, Yamaguchi, Japan, 755-8505
        • Yamaguchi University Hospital
  • Korea, Republic of
      • Seoul, Korea, Republic of, 03080
        • Seoul National University Hospital
      • Seoul, Korea, Republic of, 05505
        • Asan Medical Center
      • Seoul, Korea, Republic of, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, Korea, Republic of, 06351
        • Samsung Medical Center
  • Netherlands
      • Amsterdam, Netherlands, 1081 HV
        • VU University Medical Center
      • Amsterdam, Netherlands, 1066 CX
        • Antoni van Leeuwenhoek Ziekenhuis
      • Breda, Netherlands, 4819 EV
        • Amphia Ziekenhuis
      • Eindhoven, Netherlands, 5623 EJ
        • Catharina Ziekenhuis
      • Groningen, Netherlands, 9713 GZ
        • University Medical Center Groningen
  • Russian Federation
      • Ivanovo, Russian Federation, 153013
        • Ivanovo Regional Oncology Dispensary
      • Moscow, Russian Federation, 117997
        • Russian Scientific Center of Roentgenoradiology
      • Moscow, Russian Federation, 115478
        • N.N. Blokhin NMRCO
      • Moscow, Russian Federation, 125284
        • National Medical Research Radiological Centre
      • Ryazan', Russian Federation, 390046
        • Ryazan Regional clinical oncology dispensary
      • Saint Petersburg, Russian Federation, 199106
        • Pokrovskaya City Hospital
      • Ufa, Russian Federation, 450081
        • Clinic of Bashkortostan State Medical University
    • Leningrad Region, Vsevolozhsky District
      • Saint Petersburg, Leningrad Region, Vsevolozhsky District, Russian Federation, 188663
        • Leningrad Regional Oncology Dispensary
  • Spain
      • Barcelona, Spain, 08003
        • Hospital del Mar
      • Barcelona, Spain, 08041
        • Hospital de la Santa Creu i Sant Pau
      • Barcelona, Spain, 08035
        • Hospital Vall D Hebron
      • Madrid, Spain, 28007
        • Hospital General Universitario Gregorio Marañón
      • Madrid, Spain, 28033
        • MD Anderson Cancer Center Madrid
      • Málaga, Spain, 29010
        • Hospital Universitario Virgen de la Victoria
      • Santiago De Compostela, Spain, 15706
        • Hospital Clinico Universitario de Santiago
      • Valencia, Spain, 46009
        • Instituto Valenciano de Oncologia
  • Taiwan
      • Kaohsiung, Taiwan, 833
        • Chang Gung Medical Foundation. Kaohsiung Branch
      • Taichung, Taiwan, 40447
        • China Medical University Hospital
      • Tainan, Taiwan, 704
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 100
        • National Taiwan University Hospital
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
  • Turkey
      • Adana, Turkey, 01370
        • Adana Şehir Hastanesi
      • Ankara, Turkey, 06200
        • Dr. Abdurrahman Yurtaslan Ankara Onkoloji EAH
      • Antalya, Turkey, 07059
        • Akdeniz Universitesi Tip Fakultesi
      • Denizli, Turkey, 20070
        • Pamukkale Unv. Tip Fak.
      • Edirne, Turkey, 22030
        • Trakya Universitesi Tip Fakultesi
      • Istanbul, Turkey, 34899
        • Marmara Universitesi Pendik Arastirma ve Uyg. Hastanesi
      • Samsun, Turkey, 55200
        • Samsun Medical Park Hastanesi
      • İzmir, Turkey, 35340
        • Dokuz Eylul University Faculty of Medicine
  • United Kingdom
      • Birmingham, United Kingdom, B15 2TH
        • Queen Elizabeth Hospital
      • London, United Kingdom, NW3 2QG
        • Royal Free London NHS Foundation Trust
      • London, United Kingdom, W6 8RF
        • Imperial College Healthcare NHS Trust
      • London, United Kingdom, EC1A 7BE
        • Barts Health NHS Trust - St Bartholomew s Hospital
      • Plymouth, United Kingdom, PL6 8DH
        • Plymouth Hospitals NHS Trust
      • Sunderland, United Kingdom, SR4 7TP
        • Sunderland Royal Hospital
    • Surrey
      • Sutton, Surrey, United Kingdom, SM2 5PT
        • Royal Marsden NHS Trust
  • United States
    • Arizona
      • Chandler, Arizona, United States, 85224
        • Ironwood Cancer & Research Centers
    • California
      • Orange, California, United States, 92868
        • University of California Irvine Medical Center
      • San Francisco, California, United States, 94158
        • UCSF Helen Diller Family Comprehensive Cancer Center
      • Santa Monica, California, United States, 90404
        • UCLA Hematology Oncology Santa Monica
    • Connecticut
      • New Haven, Connecticut, United States, 06510
        • Smilow Cancer Center at Yale-New Haven
    • Georgia
      • Atlanta, Georgia, United States, 30341
        • Northside Hospital, Inc. - GCS/Annex
    • Illinois
      • Chicago, Illinois, United States, 60637
        • University of Chicago
      • Quincy, Illinois, United States, 62301
        • Quincy Medical Group
    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan Health System
    • New York
      • New York, New York, United States, 10016
        • NYU Clinical Cancer Center
    • Oklahoma
      • Tulsa, Oklahoma, United States, 74146
        • Oklahoma Cancer Specialists & Research Institute
    • Oregon
      • Portland, Oregon, United States, 97210
        • Oregon Health & Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19111
        • Fox Chase Cancer Center
      • Philadelphia, Pennsylvania, United States, 19104
        • University of Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Thomas Jefferson University Hospital
    • South Carolina
      • Charleston, South Carolina, United States, 29425
        • Medical University of South Carolina-Hollings Cancer Center
    • Tennessee
      • Knoxville, Tennessee, United States, 37920
        • University of Tennessee Medical Center Knoxville
      • Nashville, Tennessee, United States, 37203
        • Vanderbilt University Medical Center
    • Texas
      • Fort Worth, Texas, United States, 76177
        • US Oncology and Research
    • Virginia
      • Fairfax, Virginia, United States, 22031
        • Virginia Cancer Specialists, PC
      • Norfolk, Virginia, United States, 23502
        • Virginia Oncology Associates
      • Richmond, Virginia, United States, 23298
        • Vcu Massey Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Histologically-confirmed diagnosis of urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra, that is transitional cell, or mixed transitional/non-transitional (predominantly transitional) cell type.
  • Progression or recurrence of urothelial carcinoma following one prior platinum containing chemotherapy regimen for metastatic or unresectable locally advanced disease. A participant who receives a neoadjuvant or adjuvant platinum-containing regimen following cystectomy for localized muscle-invasive urothelial carcinoma is acceptable (without further systemic treatment), if recurrence/progression occurs ≤ 12 months following completion of therapy.
  • Measurable disease based on RECIST v1.1.
  • Have provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated for PD-L1 analysis.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ function per protocol-defined criteria.

Exclusion Criteria:

  • Urothelial carcinoma that is suitable for local therapy with curative intent.
  • History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years.
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, without evidence of progression for at least 4 weeks by repeat imaging.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
  • Known history of or is positive for active hepatitis B (HBsAg reactive) or has active hepatitis C (HCV RNA). Note: Testing must be performed to determine eligibility.
  • Use of protocol-defined prior/concomitant therapy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Pembrolizumab 200 mg + placebo BID
Pembrolizumab + placebo
Drug: Placebo
Matching placebo administered orally twice daily.
Drug: Pembrolizumab
Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.
Other Names:
  • MK-3475
Experimental: Pembrolizumab 200 mg + Epacadostat 100 mg BID
Pembrolizumab + epacadostat
Drug: Epacadostat
Epacadostat administered orally twice daily.
Other Names:
  • INCB024360
Drug: Pembrolizumab
Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.
Other Names:
  • MK-3475

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo
Time Frame: up to 9 weeks +14 days
ORR was defined as the percentage of participants who had a complete response (CR), disappearance of all target lesions or partial response (PR), >=30% decrease in the sum of the longest diameter of target lesions per RECIST v1.1 by investigator determination.
up to 9 weeks +14 days

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo as Measured by Number of Participants Experiencing Adverse Events (AEs)
Time Frame: Up to 8 months
AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Up to 8 months
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo as Measured by Number of Participants Discontinuing Study Treatment Due to AE
Time Frame: Up to 8 months
AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Up to 8 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Incyte Corporation

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Merck Sharp & Dohme LLC

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Mark Jones, MD, Incyte Corporation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 22, 2017

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 27, 2018

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 23, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 11, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 11, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 15, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 22, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 20, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • KEYNOTE-698/ECHO-303
  • 2017-002310-31 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on UC (Urothelial Cancer)

Clinical Trials on Epacadostat

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings